Life and Consumer Sciences, University of South Africa, College of Agriculture and Environmental Sciences, Florida, Gauteng, South Africa.
Life and Consumer Sciences, University of South Africa, College of Agriculture and Environmental Sciences, Florida, Gauteng, South Africa
BMJ Open. 2022 Aug 25;12(8):e065630. doi: 10.1136/bmjopen-2022-065630.
Diabetic neuropathy (DN) is common in patients diagnosed with diabetes mellitus. This often causes peripheral nerve damage. For many years vitamin B and alpha-lipoic acid (ALA) have been regarded as components that can be used in reducing markers of inflammation and oxidative stress. In this study, we will explore the effectiveness of vitamin B and ALA as a possible treatment for diabetic mellitus/neuropathy, emphasising markers of inflammation, lipid profile, and glucose metabolism.
We will conduct a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol (PRISMA-P). The search strategies and information sources for the literature will be PubMed, Google Scholar, Web of Science and Science direct. The literature search will include studies published from inception until 30 June 2022. All included studies will be evaluated for quality and risk of bias according to the Cochrane guidelines. To investigate the stability of the results, we will conduct a sensitivity analysis of the outcomes. All data analysis will be performed using Review Manager V.5. 4.
This systematic review and meta-analysis will not require ethical approval from an institution committee as it does not have direct participants. We will obtain all our data from previous studies. The findings will be disseminated through publications in peer-reviewed journals and presented at local and international seminars and conferences.
糖尿病性神经病(DN)在被诊断为糖尿病的患者中很常见。它通常会导致周围神经损伤。多年来,维生素 B 和硫辛酸(ALA)一直被认为是可以用于降低炎症和氧化应激标志物的成分。在这项研究中,我们将探讨维生素 B 和 ALA 作为治疗糖尿病性神经病的一种可能方法,重点研究炎症标志物、血脂谱和葡萄糖代谢。
我们将按照系统评价和荟萃分析报告的首选项目(PRISMA-P)进行系统评价。文献的检索策略和信息来源将是 PubMed、Google Scholar、Web of Science 和 Science direct。文献检索将包括从成立到 2022 年 6 月 30 日发表的研究。所有纳入的研究将根据 Cochrane 指南评估其质量和偏倚风险。为了研究结果的稳定性,我们将对结局进行敏感性分析。所有数据分析将使用 Review Manager V.5.4 进行。
由于本系统评价和荟萃分析没有直接的参与者,因此不需要机构委员会的伦理批准。我们将从以前的研究中获取所有数据。研究结果将通过在同行评议期刊上发表文章以及在本地和国际研讨会和会议上展示来传播。